Welcome to the UCSF Immunoprofiler.
The mission of the UCSF Immunoprofiler is to develop a translational platform to enhance treatment efficacy, develop precision medicines, and understand the immunological basis for cancer.
We propose that cancers are ultimately discrete forms of immunopathology. By understanding the nature of the immune response, we will determine how to treat cancers and provide new targets for the next round of immunotherapies.
Find out more about us and how you can help.
August 5, 2020
NCI OCG Guest Editorial on the Immunoprofiler Consortium. (Link).
With our 5th and final consortia partner joining Immunoprofiler, our Cancer program in its current iteration is now closed. Immunoprofiler also adds a new assay (CyTOF) to its repertoire as part of its broad profiling trajectory
January 1, 2019
April 23, 2018
Investigators at the UCSF Immunoprofiler and collaborators review the current understanding of classes within the tumor immune microenvironment and its impact on immunotherapies (Link).
January 1, 2018
Pfizer officially joins the UCSF Immunoprofiler consortium.
New 'Immunoprofiler' Initiative will advance drug discovery, precision immunotherapy for cancer (Link).
January 19, 2017
UCSF Immunoprofiler begins to profile breast cancers and sarcomas.
January 4, 2017
UCSF Immunoprofiler begins to profile prostate cancers.
December 16, 2017
Abbvie officially joins the UCSF Immunoprofiler consortium.
October 11, 2016
August 15, 2016
Investigators at the UCSF Immunoprofiler discover prognostic indicators within human melanoma cancers (Link).
August 8, 2016
Investigators at the UCSF Immunoprofiler discover new mechanisms that the immune system uses to recognize tumors (Link).
